Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis

Background: Recalcitrant neovascular age-related macular degeneration (rnAMD) despite intensive intravitreal anti-neovascular endothelial growth factor (VEGF) treatment, can be handled by switching to another anti-VEGF agent. This first systematic review and meta-analysis presents long-term data aft...

Full description

Bibliographic Details
Main Authors:	Christof Hänsli, Christin Schild, Isabel Pfister, Justus G. Garweg
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	Life
Subjects:	neovascular age-related macular degeneration brolucizumab switch meta-analysis anti-VEGF recalcitrant nAMD
Online Access:	https://www.mdpi.com/2075-1729/13/3/814

Similar Items

Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
by: Sanjay Kumar Mishra, et al.
Published: (2022-07-01)

Anatomical and functional responses to single brolucizumab injection in neovascular age-related macular degeneration patients not responding to antiangiogenics: a case series
by: Silvio Zuccarini, et al.
Published: (2022-03-01)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022-04-01)

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration
by: Joseph M. Coney, et al.
Published: (2023-02-01)

Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
by: Nadia Zakaria, et al.
Published: (2022-04-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
by: Justus G. Garweg, et al.
Published: (2023-01-01)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022-05-01)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
by: Christof Haensli, et al.
Published: (2021-06-01)

Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-Related Macular Degeneration
by: Avaylon J, et al.
Published: (2020-05-01)

Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
by: Ryan Zubricky, et al.
Published: (2023-06-01)

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01)

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
by: Prem Patel, et al.
Published: (2021-05-01)

Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study
by: Chakraborty D, et al.
Published: (2023-08-01)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
by: Emilia Maggio, et al.
Published: (2022-09-01)

Intraocular Inflammation Secondary to Intravitreal Brolucizumab Injection for Neovascular Age-Related Macular Degeneration in a Patient with Cognitive Impairment
by: Natsuki Ueji, et al.
Published: (2023-10-01)

A novel small molecule anti-VEGF drug Brolucizumab in the treatment of neovascular age-related macular degeneration
by: Tong Wu, et al.
Published: (2022-05-01)

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
by: Reem H. ElSheikh, et al.
Published: (2022-11-01)

Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review
by: Justus G. Garweg, et al.
Published: (2023-07-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
by: Chakraborty D, et al.
Published: (2021-09-01)

Efficacy of a single injection of brolucizumab in neovascular age-related macular degeneration on visual acuity and micromorphometry
by: Shrinivas Joshi, et al.
Published: (2023-01-01)

Demographic and Clinical Factors that Influence the Visual Response to Anti-Vascular Endothelial Growth Factor Therapy in Patients with Neovascular Age-Related Macular Degeneration: A Systematic Review
by: Claire R. Gill, et al.
Published: (2020-08-01)

Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration
by: Stephan Szegedi, et al.
Published: (2022-05-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
by: Chakraborty D, et al.
Published: (2022-12-01)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
by: Mehta N, et al.
Published: (2023-02-01)

LRG1 Expression Is Elevated in the Eyes of Patients with Neovascular Age-Related Macular Degeneration
by: Lucia Mundo, et al.
Published: (2021-08-01)

Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study
by: Debdulal Chakraborty, et al.
Published: (2023-01-01)

Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
by: Yingbin Fu, et al.
Published: (2024-02-01)

One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment
by: Hironori Takahashi, et al.
Published: (2024-04-01)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
by: Amoaku W, et al.
Published: (2018-09-01)

Biomarkers in Early Response to Brolucizumab on Pigment Epithelium Detachment Associated with Exudative Age-Related Macular Degeneration
by: Marco Rispoli, et al.
Published: (2021-06-01)

Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
by: Federico Ricci, et al.
Published: (2020-11-01)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019-07-01)

Short-Term Morphofunctional Changes in Previously Treated Neovascular AMD Eyes Switched to Brolucizumab
by: Pasquale Viggiano, et al.
Published: (2022-09-01)

Experimental Models in Neovascular Age Related Macular Degeneration
by: Olivia Rastoin, et al.
Published: (2020-06-01)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Rush RB
Published: (2023-08-01)

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
by: Anthony Gigon, et al.
Published: (2022-08-01)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Rush RB, et al.
Published: (2022-12-01)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
by: Pongsachareonnont P, et al.
Published: (2018-09-01)

Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy
by: Nair AA, et al.
Published: (2022-09-01)

Intravitreal Injection of Brolucizumab for Recalcitrant Macular Edema due to Central Retinal Vein Occlusion: A Small Case Series
by: Debdulal Chakraborty, et al.
Published: (2022-11-01)